Introduction {#sec1}
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Although total knee arthroplasty (TKA) is overall a safe procedure, the risk of complications such as venous thromboembolism (VTE) still remains. VTE includes deep venous thrombosis (DVT) and/or pulmonary embolism (PE) and occurs as a result of Virchow's triad: venous stasis, endothelial injury, and hypercoagulability \[[@bib1]\]. The goal of multimodal VTE prevention is to reduce each of these associated variables; chemoprophylaxis targets the hypercoagulable state, while patient mobilization and mechanical pneumatic compression devices decrease venous stasis. The historically reported rates of VTE after lower extremity arthroplasty range from 1% to 15% \[[@bib2], [@bib3], [@bib4], [@bib5]\]. Modern-day rates of symptomatic VTE have decreased substantially in part due to improvements in perioperative protocols and early mobilization \[[@bib6], [@bib7], [@bib8], [@bib9], [@bib10], [@bib11]\].

With these improvements in VTE prevention, chemoprophylaxis has shifted away from higher risk medications such as warfarin to drugs with a lower incidence of bleeding such as aspirin (ASA) \[[@bib12]\]. In many patients, ASA is as effective as Coumadin, low-molecular-weight heparin, and Factor Xa inhibitors in prevention of VTE \[[@bib13]\]. Furthermore, low-dose 81-mg ASA given twice daily has shown to be as effective as higher dose of 325-mg ASA \[[@bib6]\]. Those patients with a higher risk profile including obesity and/or history of VTE are still commonly recommended to have a stronger prophylaxis rather than ASA \[[@bib14],[@bib15]\].

Along with anticoagulant medication, mechanical pneumatic compression has been shown to decrease rates of symptomatic VTE after TKA \[[@bib16]\]. The symptomatic VTE rates using mechanical compression alone have been reported at 0.92%, which is comparable with more aggressive anticoagulation protocols \[[@bib17]\]. In addition, prolonged outpatient use of pneumatic compression further decreases the incidence of VTE over isolated inpatient use \[[@bib18]\].

The study authors have been performing outpatient TKA at a free-standing ambulatory surgery center since 2013 using an ASA -based, multimodal, and risk-stratified approach for venous thromboembolic disease prevention \[[@bib19]\]. The authors have published on the safety of outpatient arthroplasty \[[@bib20],[@bib21]\]; however, a detailed analysis of VTE in this population has not been performed. The purpose of this study is to evaluate the incidence of symptomatic VTE in patients undergoing outpatient TKA using an ASA -based risk-stratified protocol along with ambulatory portable pneumatic compression device as VTE prophylaxis.

Material and Methods {#sec2}
====================

A retrospective review of all outpatient primary TKA procedures in which patients used ambulatory pneumatic compression pumps (Compression Solutions LLC, Tulsa, OK) as part of their multimodal VTE prophylaxis was performed from 2016 through 2018. During this study period, the institution's protocol was to prescribe ambulatory compression pumps to all patients undergoing arthroplasty. Patients were excluded if they declined research (119 patients), had missing records of discharge anticoagulant medication (61 patients), or refused ambulatory calf pumps (11 patients). This yielded a cohort of 1131 patients (1453 TKAs).

All surgeries were performed with the use of tourniquet and all patients received oral or intravenous tranexamic acid. Peripheral nerve blocks were performed to include an adductor canal and posterior capsular block. A periarticular injection was performed with local anesthetic and epinephrine. General endotracheal anesthesia was used in all patients. Patients typically ambulated within 2 hours of surgery and were discharged once all criteria were met.

An ASA-based VTE prophylaxis protocol was used with patients of standard VTE risk receiving either 81 mg or 325 mg of ASA twice daily for 6 weeks postoperatively. Our standard protocol switched to 81 mg of ASA in 2017. Higher risk patients received a stronger chemoprophylaxis (fondaparinux, enoxaparin, rivaroxaban, etc.) for 2 weeks followed by ASA for 4 weeks unless the patient had an ASA contraindication.

There is currently no validated tool to stratify patients as "high risk" for VTE \[[@bib22]\]. In collaboration with our internal medicine colleagues, patients were determined to be at high risk if they were obese with a body mass index (BMI) \>40 kg/m^2^, had a history of VTE event, were in a hypercoagulable state, and/or had active cancer. All patients, regardless of risk or chemoprophylaxis, were discharged with ambulatory pneumatic compression pumps and instructed to wear them for 23 hours/day for 14 days after surgery.

Office notes and outside medical treatment documents were reviewed for duplex ultrasounds performed and confirmed VTE events of DVT and/or PE. Surgery center and durable medical equipment records were reviewed to confirm patients received the ambulatory pneumatic compression pumps. Postoperative discharge VTE medication was recorded.

All patients signed a general research consent, approved and monitored by an independent institutional review board (Western IRB, Puyallup, WA), which allows inclusion in retrospective reviews.

Results {#sec3}
=======

The mean patient age was 59.1 years (range, 25 to 81 years), and the mean BMI was 35.2 kg/m^2^ (range, 18 to 66 kg/m^2^). The gender was female in 58% of patients. Patients were considered morbidly obese (BMI \>40 kg/m^2^) in 267 (18.4%) procedures. Ninety-seven (6.7%) patients had a preoperative history of VTE event. VTE prophylaxis medication was 81 mg of ASA in 56% of patients, 325 mg of ASA in 10% of patients, and stronger chemoprophylaxis in 34% of patients.

A total of 49 duplex ultrasounds were performed (3.3% of TKAs). Confirmed VTE events were documented in only 5 (0.3%) patients. This included 3 DVTs and 2 PEs. Four of the five patients with VTE were morbidly obese. All VTEs occurred in high-risk patients who were discharged on stronger chemoprophylaxis: fondaparinux in 4 patients and rivaroxaban in 1 patient. Two of the five patients with VTE had a previous history of VTE event. The time (days) to VTE was 3, 3, 7, 45, and 88 days.

Discussion {#sec4}
==========

The principal finding of this study was the use of portable pneumatic compression pumps as part of a multimodal ASA -based VTE prophylaxis protocol aided in a very low rate of symptomatic VTE events in patients undergoing outpatient primary TKA. The only VTE events that occurred were in "high-risk patients," denoting a 0% symptomatic VTE incidence in standard-risk patients treated with ASA and ambulatory pneumatic compression pumps.

The efficacy of a risk-stratified VTE prophylaxis protocol as used in this study is supported by other surgeons. Nam et al. used a protocol in which standard-risk patients were treated with ASA and portable compressive devices for 10 days, whereas those patients determined to be at "high risk" were given warfarin therapy and only compression devices while an inpatient. They reported a VTE incidence of 0.5% using this protocol. After their initial promising results, their study institution removed obesity, age \>70 years, and multiple medical comorbidities from being "high risk" and treated these patients with the same ASA-based portable pneumatic protocol. With this change, 83% of patients were categorized as standard risk, and there was no significant difference in VTE events in this standard-risk group \[[@bib15]\]. Our institution has continued to view obese patients as "high risk," but neither medical comorbidities (outside of hypercoagulable states) nor advanced age is routinely treated with higher risk prophylaxis.

The last clinical practice guidelines produced by the American Academy of Orthopaedic Surgeons on VTE prophylaxis in arthroplasty were published in 2011. The recommendation from those clinical practice guidelines was for either pharmacologic or mechanical VTE prophylaxis \[[@bib23]\]. The subsequent guidelines from the American College of Chest Physicians echoed similar recommendations. Chemoprophylaxis and pneumatic compression devices were both given "grade 1" recommendations, which denotes there was certainty that the benefits of these treatments outweighed the potential risks \[[@bib24]\]. No subsequent guidelines have been published, but there is a fair amount of research that can aid in supporting the use of ambulatory compression pumps \[[@bib25], [@bib26], [@bib27]\].

The higher risk of bleeding events with stronger chemoprophylaxis has led many surgeons and researchers toward the use of ASA -based VTE prophylaxis regimens \[[@bib6],[@bib12],[@bib13],[@bib25]\]. Parvizi et al reported a 0.1% to 0.3% incidence of VTE in a low-risk VTE population undergoing lower extremity arthroplasty with ASA chemoprophylaxis \[[@bib6]\]. In that study, high-risk patients, such as those with a history of VTE or morbid obesity, were excluded, and patients only wore compression devices in the hospital \[[@bib6]\]. The standard-risk patients in the present study had a very similar rate of symptomatic VTE.

The use of mobile compression devices alone or with ASA after lower extremity arthroplasty has shown similar VTE rates to more potent chemoprophylaxis in standard-risk patients \[[@bib25], [@bib26], [@bib27]\]. In a multicenter analysis, Colwell et al. reported a VTE incidence of 0.92% in 3060 low-risk patients who used ambulatory compression pumps alone after hip and knee arthroplasty. This incidence was noninferior to patients receiving chemoprophylaxis alone \[[@bib26]\]. Colwell et al previously performed a randomized study of ambulatory pumps compared with heparin and found that pumps had equivalent incidence of DVT and VTE as well as significantly less bleeding events \[[@bib27]\]. Similarly, Arsoy et al. reported no difference in the VTE rates between mobile compression devices with ASA compared with low-molecular-weight heparin with significantly less bleeding events and related complications with the compression device group \[[@bib25]\].

Some concerns have arisen about patient compliance with the use of portable compression devices. However, given the lightweight and small size of these devices, a relatively high level of compliance has been reported \[[@bib15],[@bib28]\]. Froimson et al. compared a mobile, sequential, and pneumatic compression device with a nonmobile, nonsequential device. Compliance was 83% in the mobile group compared with 49% in the nonmobile group. Furthermore, the mobile group had a nearly 3 times lower DVT rate at 1.3% \[[@bib28]\]. Nam et al noted 84.5% compliance of wearing the mobile compression pumps for greater than 18 hours/day \[[@bib15]\].

This study has several limitations. First are the inherent shortcomings of a retrospective review such as inaccuracies of documentation. For example, more patients may have had a VTE event that was potentially not documented. The retrospective review also provides lower quality of evidence than a prospective randomized study or case-control study. Unfortunately, a historical control group was not available for analysis. The purpose of this research, however, was not to show superiority of one treatment over another but rather demonstrate the overall safety and effectiveness of a risk-based VTE prophylaxis model. The lack of a control group limits the conclusions that can be drawn about the ambulatory calf pump\'s effectiveness alone as all patients had other forms of VTE prophylaxis including chemoprophylaxis and early mobilization. Another limitation is the heterogenicity in chemoprophylactic medication. Even within the ASA treatment group, some patients received 325 mg and some 81 mg. However, this diversity in medication use reflects real-world practices as part of a risk-based VTE prophylaxis protocol. We were also not able to quantify how compliant the patients were with the use of the pneumatic compression devices. Devices, although capable, were not interrogated for compliance.

Conclusion {#sec5}
==========

The use of portable pneumatic compression pumps as part of an ASA-based multimodal VTE prophylaxis protocol aided in a very low rate of symptomatic VTE events in patients undergoing outpatient primary TKA.
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